» Articles » PMID: 6840175

Enzyme-inducing Drug Combinations and Their Effects on Liver Microsomal Enzyme Activity in Man

Overview
Specialty Pharmacology
Date 1983 Jan 1
PMID 6840175
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

The effect of 2 different drug combinations on liver microsomal activity was investigated in healthy volunteers by administering antipyrine 1200 mg and phenobarbitone 100 mg, or the same dose of antipyrine with rifampicin 600 mg daily for 14 days. The effect of rifampicin 1200 mg given for only 8 days was also studied. Before and after each drug regimen, estimates were made of the total body clearance of antipyrine, gamma-glutamyl-transferase (gamma-GT) and urinary excretion of 6-beta-hydroxycortisol as in vivo parameters of liver microsomal enzyme activity. Following combined antipyrine and phenobarbitone administration, the antipyrine clearance was increased by 80%, after antipyrine with rifampicin by 128%, and after rifampicin alone by 104%. 6-beta-hydroxycortisol, corrected for 17-hydroxycorticosteroids, increased from 2.6% to 8% following antipyrine plus phenobarbitone, from 4.4% to 27.9% following antipyrine plus rifampicin, and from 5.4% to 29.7% after rifampicin given alone. Based on previous studies, antipyrine given with phenobarbitone produced slightly more induction than phenobarbitone given alone. Following antipyrine 1200 mg with rifampicin 600 mg for 14 days a significantly greater increase in antipyrine clearance and 6-beta-hydroxycortisol excretion was observed than when either drug was given alone.

Citing Articles

Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P-glycoprotein-cytochrome P450 3A4 dual substrates.

Pan X, Yamazaki S, Neuhoff S, Zhang M, Pilla Reddy V CPT Pharmacometrics Syst Pharmacol. 2021; 10(12):1485-1496.

PMID: 34729944 PMC: 8674000. DOI: 10.1002/psp4.12717.


Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Galteau M, Shamsa F Eur J Clin Pharmacol. 2003; 59(10):713-33.

PMID: 14605790 DOI: 10.1007/s00228-003-0690-3.


Increases in metabolism of valproate and excretion of 6beta-hydroxycortisol in patients with traumatic brain injury.

Anderson G, Awan A, Adams C, Temkin N, Winn H Br J Clin Pharmacol. 1998; 45(2):101-5.

PMID: 9491821 PMC: 1873360. DOI: 10.1046/j.1365-2125.1998.00652.x.


A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients.

Perucca E, Hedges A, Makki K, Ruprah M, Wilson J, Richens A Br J Clin Pharmacol. 1984; 18(3):401-10.

PMID: 6435654 PMC: 1463658. DOI: 10.1111/j.1365-2125.1984.tb02482.x.


Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis.

Hoensch H, Balzer K, Dylewizc P, Kirch W, Goebell H, Ohnhaus E Eur J Clin Pharmacol. 1985; 28(4):475-7.

PMID: 4029252 DOI: 10.1007/BF00544371.


References
1.
Vesell E . The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clin Pharmacol Ther. 1979; 26(3):275-86. DOI: 10.1002/cpt1979263275. View

2.
Miguet J, Mavier P, Soussy C, Dhumeaux D . Induction of hepatic microsomal enzymes after brief administration of rifampicin in man. Gastroenterology. 1977; 72(5 Pt 1):924-6. View

3.
Prescott L . Pharmacokinetic drug interactions. Lancet. 1969; 2(7632):1239-43. DOI: 10.1016/s0140-6736(69)90766-1. View

4.
Tredger J, Smith H, Davis M, Williams R . Effect of rifampicin on the mouse hepatic mixed-function oxidase system. Biochem Pharmacol. 1981; 30(10):1043-51. DOI: 10.1016/0006-2952(81)90440-8. View

5.
Szasz G . A kinetic photometric method for serum gamma-glutamyl transpeptidase. Clin Chem. 1969; 15(2):124-36. View